Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Flynn on Obinutuzumab for the Treatment of CLL

August 25th 2014

Joseph M. Flynn, DO, MPH, discusses the results of the phase II GAGE study, which compared 1000 mg vs 2000 mg of obinutuzumab in patients with chronic lymphocytic leukemia (CLL).

Lenalidomide Plus R-CHOP Effective in Aggressive DLBCL Subtype

August 19th 2014

The addition of lenalidomide to R-CHOP demonstrated promising efficacy in previously untreated patients with diffuse large B-cell lymphoma across all subtypes of the disease.

International Hematology/Oncology Elective: A Unique Learning Experience

August 14th 2014

Although minor institution-specific variations exist, traditional fellowship programs in the United States are able to provide training in the sophisticated Western style of practice.

Attacking Acquired Mutations: Researchers Aim to Make Molecularly Targeted Cancer Therapies "Smarter"

August 8th 2014

Hailed as "new ammunition in the war against cancer" and featured in TIME magazine at the turn of the new millennium, molecularly targeted therapies have gone on to revolutionize cancer treatment. Clinical responses, however, are all too often short-lived as cancer cells become resistant.

FDA Grants Priority Review to Ruxolitinib in Polycythemia Vera

August 5th 2014

The FDA has assigned a priority review designation to the JAK1/2 inhibitor ruxolitinib as treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea

Carfilzomib Combination Effective for Relapsed Myeloma

August 4th 2014

The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and low-dose dexamethasone extended progression-free survival (PFS) by 8.7 months compared with lenalidomide and dexamethasone alone for patients with relapsed multiple myeloma

FDA Expands Ibrutinib's CLL Approval

July 28th 2014

The FDA has expanded the approval of ibrutinib to include the treatment of patients with chronic lymphocytic leukemia who have received at least one previous therapy and harbor a 17p deletion.

Dr. Flynn Discusses Ibrutinib for Hematologic Malignancies

July 28th 2014

Joseph M. Flynn, DO, MPH, co-director, Division of Hematology; co-director, LIVESTRONG Survivorship Center of Excellence; medical director, James Survivorship Clinics, The Ohio State University, James Cancer Hospital, discusses the impact ibrutinib has had on treating hematologic malignancies.

Ruxolitinib Outperforms Standard Therapy in Polycythemia Vera

July 24th 2014

In the first pivotal phase III study of a Janus-associated kinase (JAK) inhibitor for the treatment of polycythemia vera (PV), ruxolitinib (Jakafi) was superior to best available therapy (BAT) in maintaining control of hematocrit without the need for phlebotomy and in reducing spleen size in patients with an inadequate response to or intolerance of hydroxyurea.

FDA Approves Idelalisib for CLL, SLL, and Follicular Lymphoma

July 23rd 2014

The FDA has approved idelalisib in combination with rituximab for patients with high-risk relapsed or refractory CLL and as a single-agent for two types of iNHL.

ASCO 2014: Gearing Up for More Changes

July 21st 2014

The ASCO annual meeting is always a time of excitement for the nearly 30,000 clinicians and scientists who gather every year to see "what's new."

IDH2 Inhibitor Shows Promise in AML

July 18th 2014

An early study presented at the 2014 AACR Annual Meeting showed promise for a new targeted therapy for acute myeloid leukemia

CLL Researcher Excited About Outlook for CDK Inhibitors

July 17th 2014

Joseph Flynn, DO, MPH, focuses on the development of novel therapeutics for the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) in his research at The Ohio State University Comprehensive Cancer Center.

First CAR Therapy Receives FDA Breakthrough Designation

July 8th 2014

The investigational CD19-targeted CAR therapy CTL019 has received a breakthrough therapy designation from the FDA as a potential treatment for pediatric and adult patients with relapsed/refractory ALL.

FDA Approves Belinostat for Peripheral T-Cell Lymphoma

July 3rd 2014

The FDA has approved belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

Novel Epigenetic Therapy Shows Clinical Activity in Hematologic Malignancies

July 2nd 2014

Preliminary evidence supports the use of bromodomain inhibitors in hematologic malignancies, including acute leukemia (mainly acute myelogenous leukemia) and other hematological malignancies, including diffuse large B-cell lymphoma and multiple myeloma.

Blinatumomab Receives Breakthrough Therapy Designation for ALL

July 1st 2014

The FDA has granted a breakthrough therapy designation to blinatumomab for the treatment of adult patients with Philadelphia-negative relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)

Ofatumumab Misses PFS Endpoint in Bulky CLL

June 30th 2014

Ofatumumab (Arzerra) failed to meet its primary endpoint of improvement in progression-free survival (PFS) in a phase III study of the drug versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukemia (CLL),

MRD: The Next Frontier in Oncology

June 19th 2014

The measurement of response to anticancer therapy has evolved over the years as a result of better therapies and progress in imaging.

Dr. Carson Discusses Mogamulizumab as Potential Treatment for CTCL

June 18th 2014

Kenneth R. Carson, MD, assistant professor, Division of Oncology, Washington University, discusses mogamulizumab as a potential treatment for patients with relapsed or refractory cutaneous T cell lymphoma (CTCL).